Glecirasib

DRUG2 trials

Sponsors

Sun Yat-sen University, Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Conditions

KRAS G12CLung Cancer Stage IIIMutationNSCLC Stage IV

Phase 1

Glecirasib Combined With Ivonescimab for First-line Treatment of KRAS G12C-mutated NSCLC

Not yet recruitingNCT07339839

Cancer Institute and Hospital, Chinese Academy of Medical SciencesKRAS G12C, NSCLC Stage IV

Start: 2026-03-01End: 2029-09-30Target: 42Updated: 2026-01-14

Phase 2

Neoadjuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harboring Rare Mutations.

RecruitingNCT06563999

Sun Yat-sen UniversityLung Cancer Stage III, Mutation

Start: 2024-11-01End: 2029-11-01Target: 120Updated: 2024-12-10